Pharmaceuticals & Biotech Nigerian Community

Executive Summary Neimeth International Pharmaceuticals Plc (“Neimeth” or “the Company”) reported moderate growth in revenue and profitability for the nine months ended September 30, 2025. Total revenue for the period increased 62% YoY to ₦5.01 billion , driven primarily by improved sales volumes and better market penetration.Read more

Executive Summary Fidson Healthcare Plc delivered a strong performance for the nine months ended September 30, 2025, supported by robust revenue growth, operational efficiency, and disciplined financial management. Despite currency volatility and macroeconomic headwinds, the Group sustained earnings momentum through strategic cost control, expanded product offerings, and improved working capital management.Read more

MeCure Industries Plc has delivered exceptional growth in Q2 2025, highlighted by a 634% YoY surge in pre-tax profit and 165% revenue growth , driven primarily by booming demand in its acute care and OTC product segments. The company’s sharp revenue and margin expansion have firmly placed it on an upward profitability trajectory.Read more